Teijin will support development and commercialisation in Japan of BioVaram’s pipeline, including exosome-based diagnostics and therapeutics, extracellular matrix (ECM) mimics, and bio-derived materials such as Type I atelocollagen
Teijin will support development and commercialisation in Japan of BioVaram’s pipeline, including exosome-based diagnostics and therapeutics, extracellular matrix (ECM) mimics, and bio-derived materials such as Type I atelocollagen